PicoCELA Inc. (NASDAQ:PCLA) Sees Large Drop in Short Interest

Posted by James Conley on Mar 29th, 2026

PicoCELA Inc. (NASDAQ:PCLA – Get Free Report) was the target of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 8,317 shares, a decline of 23.5% from the February 26th total of 10,866 shares. Currently, 20.8% of the shares of the company are short sold. Based on an average daily trading volume, of 18,324 shares, the short-interest ratio is presently 0.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a report on Friday, January 9th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Get Our Latest Analysis on PicoCELA

Institutional Trading of PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd bought a new position in shares of PicoCELA Inc. (NASDAQ:PCLA – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned approximately 0.16% of PicoCELA as of its most recent SEC filing.

PicoCELA Stock Performance

PCLA stock opened at $2.06 on Friday. PicoCELA has a fifty-two week low of $1.94 and a fifty-two week high of $112.20. The company has a current ratio of 2.13, a quick ratio of 1.57 and a debt-to-equity ratio of 0.02. The business’s fifty day moving average price is $4.22 and its two-hundred day moving average price is $8.38.

About PicoCELA

(Get Free Report)

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.